Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

saccharomyces boulardii and Reduced Diarrhea Rate

Research synthesisModerate evidenceModerate effect7 studies · 5 beneficial · 2 neutral · 0 harmful

Across 7 studies, 5 reported beneficial effects of Saccharomyces boulardii on reducing diarrhea rates, with effect sizes ranging from moderate to large, while 2 studies found neutral results. The most commonly evaluated dose was 250 mg twice daily or 500 mg/day, and the strongest evidence comes from children with acute diarrhea and patients on antibiotic or radiotherapy regimens. Most studies were short-term (under 2 weeks), and no consistent form information was reported.

  • Effective dose range: 250 mg twice daily (500 mg/day) to 1000 mg/day
  • Studied populations: children with acute diarrhea, hospitalized patients at risk for antibiotic-associated diarrhea, patients undergoing pelvic radiotherapy for gynecologic cancers

Caveats: Available evidence is overwhelmingly positive (5 of 7 studies beneficial) — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Two of the 7 studies (RCTs) were neutral and not statistically significant, suggesting the effect may be smaller or context-dependent. Most studies were short-term (acute diarrhea episodes, not long-term prophylaxis), and dose reporting was incomplete in several abstracts.

Generated May 21, 2026
Doses used in studies
  • mg/day: 250–2,000 (median 625, IQR 437.5–1,250) — 4 studies
Safety in these studies
7 of 7 papers
Back to top